Abstract: The present invention offers a solution to the lack of an effective alternative method to those already known to treat angiogenesis. In particular, the present invention is the first to show that a substantially pure population of exosomes derived from MenSCs have capacity to reduce tumor angiogenesis in diseases such as prostate cancer, breast cancer and pancreatic cancer. In this sense, the present invention shows that a substantially pure population of MenSCs-derived exosomes reduce the endogenous levels of reactive oxygen species (ROS) in cancer cells and the expression of pro-angiogenic factors such as VEGF, NF-KB, FGF and HIF? in the treated tumors. Overall, the invention offers a promising alternative method to treat angiogenesis. Since it is principally composed of exosomes produced by the Stem cells present in menstrual fluid, the invention provides an ease access and repeated sampling in a non-invasive manner. Such attributes allow the rapid production of the treatment.

Abstract: The present invention offers a solution to the lack of an effective alternative method to those already known to treat angiogenesis. In particular, the present invention is the first to show that a substantially pure population of exosomes derived from MenSCs have capacity to reduce tumor angiogenesis in diseases such as prostate cancer, breast cancer and pancreatic cancer. In this sense, the present invention shows that a substantially pure population of MenSCs-derived exosomes reduce the endogenous levels of reactive oxygen species (ROS) in cancer cells and the expression of pro-angiogenic factors such as VEGF, NF-KB, FGF and HIF? in the treated tumors. Overall, the invention offers a promising alternative method to treat angiogenesis. Since it is principally composed of exosomes produced by the Stem cells present in menstrual fluid, the invention provides an ease access and repeated sampling in a non-invasive manner. Such attributes allow the rapid production of the treatment.

Abstract: The present invention offers a solution to the lack of effective alternative treatments to fight infectious disease, preferably involving sepsis, comprising active ingredients obtained by non-intrusive and efficient methods. In particular, the present invention is the first to show that mesenchymal stem cells obtained from menstrual fluids (MenSCs) have the capacity to control infectious diseases, especially those leading to a reaction of the host body like sepsis. As shown herein, in vivo experiments illustrate that MenSCs have antibacterial activity in vitro, increase the survival rates of a mouse model for sepsis, regulate several parameters that are altered in sepsis patients and that are related with multi-organ dysfunction, such as the levels of Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), alkaline phosphatase (ALP), glucose in blood, serum albumin, lung injury.

Abstract: A method and compound product are created from menstrual blood-derived mesenchymal stem cells (MenSCs) with an anti-tumor effect. In particular, the method and compound show the potential anti-tumor effect MenSCs can have on human pancreatic carcinoma, which has been analyzed on the Mia PaCa 2 human pancreatic carcinoma cell line (ATCC #CRL 1420). MenSCs have been proven to have an in vitro anti-tumor effect both in bi-dimensional cultures (monolayer) and in three-dimensional cultures (tumorspheres). Additionally, MenSCs slow down the appearance of pancreatic tumors when they are co-implanted with the pancreatic carcinoma cell line. MenSCs also have an in vivo therapeutic advantage in the treatment of human pancreatic carcinoma via intra-tumor injections.

Abstract: The invention relates to highly proliferative stem cell obtained from menstrual fluid. The menstrual stern cells (MenSCs) may be cultured in vitro and exhibit mesenchymal stem cell (MSC)-like properties and some culture and expansion advantages. This population of MenSCs, compared to the broadly studied bone marrow derived stem cells (BM-MSCs) out-performs bone marrow derived mesenchymal stem cells in proliferation rate and support of hematopoietic stem cell (HSC) expansion in vitro. MenSCs demonstrate to maintain their stem cell properties over 2 years, being genetically stable, without expressing surface differentiation markers, and they also show the ability to differentiate into adipocytes, chondrocytes and osteoblast cells. MenSCs can be easily and periodically obtained, isolated and cultured.